Literature DB >> 15199428

Low-density lipoprotein receptor--its structure, function, and mutations.

Joep C Defesche1.   

Abstract

Uptake of cholesterol, mediated by the low-density lipoprotein (LDL)-receptor, plays a crucial role in lipoprotein metabolism. The LDL-receptor is responsible for the binding and subsequent cellular uptake of apolipoprotein B- and E-containing lipoproteins. To accomplish this, the receptor has to be transported from the site of synthesis, the membranes of the rough endoplasmatic reticulum (ER), through the Golgi apparatus, to its position on the surface of the cellular membrane. The translation of LDL-receptor messenger RNA into the polypeptide chain for the receptor protein takes place on the surface-bound ribosomes of the rough ER. Immature O-linked carbohydrate chains are attached to this integral precursor membrane protein. The molecular weight of the receptor at this stage is 120.000 d. The precursor-protein is transported from the rough ER to the Golgi apparatus, where the O-linked sugar chains are elongated until their final size is reached. The molecular weight has then increased to 160.000 d. The mature LDL-receptor is subsequently guided to the "coated pits" on the cell surface. These specialized areas of the cell membrane are rich in clathrin and interact with the LDL-receptor protein. Only here can the LDL-receptor bind LDL-particles. Within 3 to 5 minutes of its formation, the LDL-particle-receptor complex is internalized through endocytosis and is further metabolized through the receptor-mediated endocytosis pathway. Mutations in the gene coding for the LDL-receptor can interfere to a varying extent with all the different stages of the posttranslational processing, binding, uptake, and subsequent dissociation of the LDL-particle-LDL-receptor complex, but invariably the mutations lead to familial hypercholesterolemia. Thus, mutations in the LDL-receptor gene give rise to a substantially varying clinical expression of familial hypercholesterolemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15199428     DOI: 10.1055/s-2004-822993

Source DB:  PubMed          Journal:  Semin Vasc Med        ISSN: 1528-9648


  16 in total

1.  Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.

Authors:  Yajun Duan; Yuanli Chen; Wenquan Hu; Xiaoju Li; Xiaoxiao Yang; Xin Zhou; Zhinan Yin; Deling Kong; Zhi Yao; David P Hajjar; Lin Liu; Qiang Liu; Jihong Han
Journal:  J Biol Chem       Date:  2012-05-16       Impact factor: 5.157

Review 2.  Human low-density lipoprotein receptor gene and its regulation.

Authors:  Wei-Jia Kong; Jingwen Liu; Jian-Dong Jiang
Journal:  J Mol Med (Berl)       Date:  2005-11-16       Impact factor: 4.599

3.  Activation of the TLR4 signaling pathway and abnormal cholesterol efflux lead to emphysema in ApoE-deficient mice.

Authors:  Monica Goldklang; Polina Golovatch; Tina Zelonina; Jordis Trischler; Daniel Rabinowitz; Vincent Lemaître; Jeanine D'Armiento
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-03-23       Impact factor: 5.464

4.  Caveolae in ventricular myocytes are required for stretch-dependent conduction slowing.

Authors:  E R Pfeiffer; A T Wright; A G Edwards; J C Stowe; K McNall; J Tan; I Niesman; H H Patel; D M Roth; J H Omens; A D McCulloch
Journal:  J Mol Cell Cardiol       Date:  2014-09-26       Impact factor: 5.000

5.  Hexavalent chromium-induced alteration of proteomic landscape in human skin fibroblast cells.

Authors:  Lei Guo; Yongsheng Xiao; Yinsheng Wang
Journal:  J Proteome Res       Date:  2013-06-11       Impact factor: 4.466

6.  Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone.

Authors:  Hideaki Nakaya; Barbara D Summers; Andrew C Nicholson; Antonio M Gotto; David P Hajjar; Jihong Han
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

7.  Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor.

Authors:  Sha Huang; Lisa Henry; Yiu Kee Ho; Henry J Pownall; Gabby Rudenko
Journal:  J Lipid Res       Date:  2009-08-11       Impact factor: 5.922

8.  Increased locomotor activity in mice lacking the low-density lipoprotein receptor.

Authors:  Gregory A Elder; Andre Ragnauth; Nathan Dorr; Sonia Franciosi; James Schmeidler; Vahram Haroutunian; Joseph D Buxbaum
Journal:  Behav Brain Res       Date:  2008-04-08       Impact factor: 3.332

9.  Monomethylarsonous acid inhibited endogenous cholesterol biosynthesis in human skin fibroblasts.

Authors:  Lei Guo; Yongsheng Xiao; Yinsheng Wang
Journal:  Toxicol Appl Pharmacol       Date:  2014-03-10       Impact factor: 4.219

10.  Proteomics analysis reveals a potential new target protein for the lipid-lowering effect of Berberine8998.

Authors:  Cheng-Yin Yu; Gang-Yi Liu; Xiao-Hui Liu; Yu-Zhou Gui; Hai-Ming Liu; Hong-Chao Zheng; Darek C Gorecki; Asmita V Patel; Chen Yu; Yi-Ping Wang
Journal:  Acta Pharmacol Sin       Date:  2018-04-12       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.